Literature DB >> 25817132

Iron, inflammation and atherosclerosis risk in men vs. perimenopausal women.

Subha V Raman1, Travis P Sharkey-Toppen2, Tam Tran2, Jim X Liu2, Beth McCarthy2, Xin He3, Suzanne Smart2, Martha Gulati2, Randell Wexler4, Orlando P Simonetti2, Rebecca D Jackson5.   

Abstract

OBJECTIVE: Age at first atherosclerotic event is typically older for women vs. men; monthly iron loss has been postulated to contribute to this advantage. We investigated the relationship between an MRI-based arterial wall biomarker and the serum inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) in perimenopausal women vs. men. METHODS AND
RESULTS: Women without evident atherosclerotic disease were prospectively enrolled and observed over 24 months of menopause transition, indicated by hormone levels and reduction in median number of menstrual cycles from 4 [3-6] per year to 0 [0-1] per year (P < 0.01). Higher hsCRP predicted shorter carotid artery wall T2* in women entering the menopause transition (r = -0.3139, P = 0.0014); this relationship weakened after 24 months of perimenopause in women (r = -0.1718, P = 0.0859) and was not significant in a cohort of men matched for age and cardiovascular risk category (r = -0.0310, P = 0.8362). Serum ferritin increased from baseline to 24-month follow-up during women's menopause transition (37 [20-79] to 67 [36-97] ng/mL, P < 0.01), but still remained lower compared to men (111 [45-220] ng/mL, P < 0.01). Circulating ferritin levels correlated with arterial wall T2* values in women at baseline (r = -0.3163, P = 0.0013) but not in women after 24 months (r = -0.0730, P = 0.4684) of menopause transition nor in men (r = 0.0862, P = 0.5644).
CONCLUSIONS: An arterial wall iron-based imaging biomarker reflects degree of systemic inflammation in younger women, whereas this relationship is lost as women transition through menopause to become more similar to men. Iron homeostasis and inflammation in the arterial wall microenvironment warrants further investigation as a potential early target for interventions that mitigate atherosclerosis risk.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Iron; Magnetic resonance imaging; Risk factors; Women

Mesh:

Substances:

Year:  2015        PMID: 25817132      PMCID: PMC4567041          DOI: 10.1016/j.atherosclerosis.2015.03.032

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  48 in total

Review 1.  Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis.

Authors:  Robin P Choudhury; Justin M Lee; David R Greaves
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2005-06

Review 2.  Ferritin in atherosclerosis.

Authors:  Sun-Ah You; Qing Wang
Journal:  Clin Chim Acta       Date:  2005-03-23       Impact factor: 3.786

3.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.

Authors:  D H O'Leary; J F Polak; R A Kronmal; T A Manolio; G L Burke; S K Wolfson
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

4.  Aromatase and breast cancer susceptibility.

Authors:  N M Probst-Hensch; S A Ingles; A T Diep; R W Haile; F Z Stanczyk; L N Kolonel; B E Henderson
Journal:  Endocr Relat Cancer       Date:  1999-06       Impact factor: 5.678

5.  Red cells, hemoglobin, heme, iron, and atherogenesis.

Authors:  Emoke Nagy; John W Eaton; Viktória Jeney; Miguel P Soares; Zsuzsa Varga; Zoltán Galajda; József Szentmiklósi; Gábor Méhes; Tamás Csonka; Ann Smith; Gregory M Vercellotti; György Balla; József Balla
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-04-08       Impact factor: 8.311

Review 6.  Atherosclerosis--an immune disease: The Anitschkov Lecture 2007.

Authors:  Göran K Hansson
Journal:  Atherosclerosis       Date:  2008-09-06       Impact factor: 5.162

7.  Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.

Authors:  Gervasio A Lamas; Christine Goertz; Robin Boineau; Daniel B Mark; Theodore Rozema; Richard L Nahin; Lauren Lindblad; Eldrin F Lewis; Jeanne Drisko; Kerry L Lee
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

8.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

Authors:  Sylvia Wassertheil-Smoller; Susan L Hendrix; Marian Limacher; Gerardo Heiss; Charles Kooperberg; Alison Baird; Theodore Kotchen; J David Curb; Henry Black; Jacques E Rossouw; Aaron Aragaki; Monika Safford; Evan Stein; Somchai Laowattana; W Jerry Mysiw
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

9.  Mechanism of in vitro heme-induced LDL oxidation: effects of antioxidants.

Authors:  K Klouche; M Morena; B Canaud; B Descomps; J J Beraud; J P Cristol
Journal:  Eur J Clin Invest       Date:  2004-09       Impact factor: 4.686

10.  Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Authors:  Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick
Journal:  JAMA       Date:  2008-03-05       Impact factor: 56.272

View more
  2 in total

1.  Novel insights into renovascular hypertension and cardio-renal protection by iron restriction.

Authors:  Atsushi Tanaka; Koichi Node
Journal:  Hypertens Res       Date:  2016-09-08       Impact factor: 3.872

2.  Transferrin predicts trimethylamine-N-oxide levels and is a potential biomarker of cardiovascular disease.

Authors:  Lamuel D Bean; Jeffrey J Wing; Randall E Harris; Suzanne M Smart; Subha V Raman; M Wesley Milks
Journal:  BMC Cardiovasc Disord       Date:  2022-05-10       Impact factor: 2.174

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.